Kangwei Century released its 2026 interim report. In the first half of the year, the company's operating revenue was 113 million yuan, up 29.7% year on year. Net profit attributable to the parent company changed from a loss of 55.91 million yuan in the same period last year to a loss of 35.18 million yuan, with the loss narrowing. Net profit attributable to the parent company after deducting non-recurring items changed from a loss of 66.56 million yuan in the same period last year to a loss of 45.39 million yuan, with the loss narrowing. Net operating cash flow was negative 28.39 million yuan, up 42.8% year on year. Earnings per share were negative 0.3128 yuan. In the second quarter, the company's operating revenue was 54.02 million yuan, up 22.5% year on year. Net profit attributable to the parent company changed from a loss of 33.17 million yuan in the same period last year to a loss of 19.83 million yuan, with the loss narrowing. Net profit attributable to the parent company after deducting non-recurring items changed from a loss of 37.79 million yuan in the same period last year to a loss of 24.8 million yuan, with the loss narrowing. Earnings per share were negative 0.1763 yuan. As of the end of the second quarter, the company's total assets were 1.486 billion yuan, down 0.7% from the end of the previous year. Net assets attributable to the parent company were 1.318 billion yuan, down 2.4% from the end of the previous year. In the interim report, the company noted that it continues to focus on independent research and development of core molecular detection technologies, and has established multiple technology platforms covering raw material enzymes, nucleic acid preservation, and sample pre-processing. It has developed more than 700 core products and provides a range of testing services around high-throughput sequencing platforms, forming an integrated layout.
Jiangsu Cowin Biotech Co. Ltd. ALoss narrowed and revenue grew in interim report
